Holen Sie sich die Stockscreener-App
8.45
3.67%
0.28
Schlusskurs vom Vortag:
$8.17
Offen:
$8.21
24-Stunden-Volumen:
1.16M
Relative Volume:
1.15
Marktkapitalisierung:
$600.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.87M
KGV:
-4.6685
EPS:
-1.81
Netto-Cashflow:
$-109.90M
1W Leistung:
+33.39%
1M Leistung:
+49.38%
6M Leistung:
-16.72%
1J Leistung:
-5.78%
1-Tages-Spanne:
$8.19
$9.4799
1-Wochen-Bereich:
$5.5148
$9.4799
52-Wochen-Spanne:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.44 | 410.89M | 0 | -119.87M | -109.90M | -1.81 |
|
ONC
Beone Medicines Ltd Adr
|
244.57 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.24 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.55 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
486.82 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
ProShare Advisors LLC Increases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Research Analysts Set Expectations for ORIC FY2025 Earnings - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down – Here’s What Happened - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat
ORIC-944 shows promise in combination with AR inhibitors in mCRPC - Urology Times
Wedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat
Deutsche Bank AG Has $464,000 Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Outperform” Rating at Wedbush - Defense World
Traders Buy Large Volume of ORIC Pharmaceuticals Call Options (NASDAQ:ORIC) - Defense World
Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial - Asianet Newsable
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials - MSN
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study - sharewise
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
ORIC Pharmaceuticals shares surge on promising trial data By Investing.com - Investing.com South Africa
ORIC Pharmaceuticals shares surge on promising trial data - Investing.com Australia
ORIC Pharma jumps on promising data from prostate cancer drug trial - TradingView
Oric Pharmaceuticals (ORIC) Shows Promising Results in Cancer Drug Trial | ORIC Stock News - GuruFocus
ORIC Pharma's Prostate Cancer Drug Shows Encouraging Early Results; Upcoming Milestones Ahead - RTTNews
ORIC Pharmaceuticals (ORIC) Secures $125M in Private Stock Sale - GuruFocus
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
Oric Pharmaceuticals (ORIC) Secures $125M in Private Placement | - GuruFocus
ORIC Pharmaceuticals (ORIC) Secures $125M to Advance R&D - GuruFocus
ORIC Pharmaceuticals secures $125 million in private placement - Investing.com India
Oric Pharmaceuticals (ORIC) Reveals Promising Phase 1b Trial Dat - GuruFocus
Oric Pharmaceuticals (ORIC) Reveals Promising Phase 1b Trial Data for Prostate Cancer Treatment | ORIC Stock News - GuruFocus
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Prelim - GuruFocus
ORIC® Pharmaceuticals Announces $125 Million Private Placement F - GuruFocus
ORIC Pharmaceuticals secures $125 million in private placement By Investing.com - Investing.com Nigeria
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - The Manila Times
ORIC Lands Massive $125M Investment Led by SR One, Extending Runway Through Critical Phase 3 Cancer Trial - Stock Titan
ORIC Pharmaceuticals Showcases Cancer Drug Pipeline at Jefferies and Goldman Healthcare Conferences - Stock Titan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals: Promising Growth Potential with Superior Safety Profile and Strong Financial Position - TipRanks
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b - GlobeNewswire
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC - The Manila Times
New Clinical Data: ORIC-944 Combination Therapy Shows Early Results for Advanced Prostate Cancer - Stock Titan
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Holdings Lowered by Frazier Life Sciences Management L.P. - MarketBeat
Janus Henderson Group PLC Acquires New Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Trading Signals - news.stocktradersdaily.com
Northern Trust Corp Increases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from Analysts - MarketBeat
Sphera Funds Management LTD. Purchases 144,817 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Average Price Target from Analysts - Defense World
NEA Management Company LLC Buys 66,081 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Dimensional Fund Advisors LP Has $5.79 Million Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Balyasny Asset Management L.P. Buys 424,194 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
115,615 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
1.76%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):